These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34787322)

  • 1. A population-based study of scoliosis among males diagnosed with a dystrophinopathy identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).
    Conway KM; Gedlinske A; Mathews KD; Perlman S; Johnson N; Butterfield R; Hung M; Bounsanga J; Matthews D; Oleszek J; Romitti PA
    Muscle Nerve; 2022 Feb; 65(2):193-202. PubMed ID: 34787322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet.
    Butterfield RJ; Kirkov S; Conway KM; Johnson N; Matthews D; Phan H; Cai B; Paramsothy P; Thomas S; Feldkamp ML
    Muscle Nerve; 2022 Jul; 66(1):15-23. PubMed ID: 34994466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic mutations and loss of ambulation in childhood-onset dystrophinopathy.
    Haber G; Conway KM; Paramsothy P; Roy A; Rogers H; Ling X; Kozauer N; Street N; Romitti PA; Fox DJ; Phan HC; Matthews D; Ciafaloni E; Oleszek J; James KA; Galindo M; Whitehead N; Johnson N; Butterfield RJ; Pandya S; Venkatesh S; Bhattaram VA
    Muscle Nerve; 2021 Feb; 63(2):181-191. PubMed ID: 33150975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.
    Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ;
    Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of cardiac medications for delay of left ventricular dysfunction in Duchenne muscular dystrophy.
    Conway KM; Thomas S; Ciafaloni E; Khan RS; Mann JR; Romitti PA; Mathews KD;
    Birth Defects Res; 2024 Jan; 116(1):e2260. PubMed ID: 37850663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.
    Ciafaloni E; Kumar A; Liu K; Pandya S; Westfield C; Fox DJ; Caspers Conway KM; Cunniff C; Mathews K; West N; Romitti PA; McDermott MP
    J Pediatr Rehabil Med; 2016; 9(1):5-11. PubMed ID: 26966795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
    Alman BA; Raza SN; Biggar WD
    J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network.
    Caspers Conway K; Mathews KD; Paramsothy P; Oleszek J; Trout C; Zhang Y; Romitti PA;
    J Dev Behav Pediatr; 2015; 36(6):455-63. PubMed ID: 26020585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy.
    Mann JR; Zhang Y; McDermott S; Wang Y; Cai B; Conway KM; Paramsothy P; Royer J; Venkatesh S; Howard JF; Ciafaloni E;
    Neuroepidemiology; 2023; 57(2):90-99. PubMed ID: 36623491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic or lumbar fixation for the surgical management of scoliosis in duchenne muscular dystrophy.
    Sengupta DK; Mehdian SH; McConnell JR; Eisenstein SM; Webb JK
    Spine (Phila Pa 1976); 2002 Sep; 27(18):2072-9. PubMed ID: 12634572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
    Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
    J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry.
    Cowen L; Mancini M; Martin A; Lucas A; Donovan JM
    BMC Neurol; 2019 May; 19(1):84. PubMed ID: 31046703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of Pediatric-Onset Duchenne and Becker Muscular Dystrophy Subphenotypes Using Data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet).
    Andrews JG; Lamb MM; Conway KM; Street N; Westfield C; Ciafaloni E; Matthews D; Pandya S;
    J Neuromuscul Dis; 2022; 9(1):171-178. PubMed ID: 34776418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001.
    Fox DJ; Kumar A; West NA; DiRienzo AG; James KA; Oleszek J;
    J Child Neurol; 2015 Jan; 30(1):21-6. PubMed ID: 24682290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of growth in ambulatory males with Duchenne muscular dystrophy.
    West NA; Yang ML; Weitzenkamp DA; Andrews J; Meaney FJ; Oleszek J; Miller LA; Matthews D; DiGuiseppi C
    J Pediatr; 2013 Dec; 163(6):1759-1763.e1. PubMed ID: 24103921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015.
    Thomas S; Conway KM; Fapo O; Street N; Mathews KD; Mann JR; Romitti PA; Soim A; Westfield C; Fox DJ; Ciafaloni E;
    Muscle Nerve; 2022 Aug; 66(2):193-197. PubMed ID: 35312090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta-analysis.
    Weber FJ; Latshang TD; Blum MR; Kohler M; Wertli MM
    Muscle Nerve; 2022 Oct; 66(4):462-470. PubMed ID: 35860996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
    Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
    J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.